Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I‐II), the 5‐year survival rate is between 70% and 90%; whereas, when it is detected in late stages (III‐IV), the 5‐year survival rate slips to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2012-01, Vol.118 (1), p.91-100
Hauptverfasser:	Moore, Lee E., Pfeiffer, Ruth M., Zhang, Zhen, Lu, Karen H., Fung, Eric T., Bast, Robert C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences biomarkers Biomarkers, Tumor - blood CA 125 CA-125 Antigen - blood Carcinoma, Ovarian Epithelial Case-Control Studies Colorectal early detection Early Detection of Cancer Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Lung Medical sciences Middle Aged Neoplasms, Glandular and Epithelial - diagnosis ovarian cancer Ovarian Cancer Screening Trial Ovarian Neoplasms - diagnosis Prostate Proteomics - methods Sensitivity and Specificity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND: When epithelial ovarian cancer is detected at an early stage (I‐II), the 5‐year survival rate is between 70% and 90%; whereas, when it is detected in late stages (III‐IV), the 5‐year survival rate slips to
ISSN:	0008-543X 1097-0142
DOI:	10.1002/cncr.26241